Mikhail Blagosklonny: A Study

Mikhail Blagosklonny is a man who wears many hats, as they say. Mikhail Blagosklonny is a philanthropist, professor, researcher and an oncologist. His long-term career goal is to make certain that everyone on the planet have convenient access to the best medical treatment available regardless of each person’s personal finances.

Study

He has a number of interests. He is mainly involved in the area of medical research. He generally focuses his professional attentions on the subjects of aging and cancer.Blagosklonny is especially interested in studying the relationship between the two previously mentioned subjects. One day he hopes he will be able to discover exactly why cancer is significantly more prevalent among adults who are past a certain age.

Current Work

He is presently concentrating on working on specific research that he believes with yield data that should be repeatedly helpful to every other researcher working in the area of oncology. Furthermore, he is said to be continuously impacting the work of other research teams both as a college professor and as an expert and field researcher in oncology. Some say that Blagosklonny also now serves as a frequent source of inspiration to not only his students but to his peers who all wish to actually expand upon Blagosklonny’s present research in the future.

Interests

Blagosklonny’s specific areas of interest within the overall areas of aging and cancer have garnered Blagosklonny a lot of interest and attention in the medical field. He is driven to not simply learn exactly how to treat cancer in general but also how to treat cancer in a way that is effective, painless and far less expensive in comparison to the numerous ways of treating cancer today. He also wants to learn how to eliminate cancerous cells in the body without damaging any healthy cells that are needed for the recovery of both the body and the mind following the months or maybe even years of treatment.

Progress

At press time, Mikhail Blagosklonny has made a great deal of progress in his areas of choice. He hopes that his many discoveries will go on to both inspire other researchers to “follow in his footsteps” and someday pick up where he will one day leave off. He also predicts that one day, the treatment of cancer will not be an expensive luxury available only to the wealthy but will be cost-effective, painless, and accessible to all cancer patients.

All About Mikhail Blagosklonny

Mikhail Blagosklonny is a professor at the Roswell Park Cancer Institute that is located in Buffalo New York. He is a scientist that studies aging and cancer and he attended First Pavlov State Medical University of St. Petersburg where he obtained an MD of Internal Medicine. Additionally, he also obtained a PhD in Experimental Medicine and Cardiology. In 2002, he was appointed the associate professor of medicine at New York Medical College in Valhalla, New York. The next place he went to was Ordway Research Institute where he was appointed the senior scientist. Finally, in 2009, he went to the Roswell Park Cancer Institute. Mikhail’s research interest includes many things. Some of those things are: Biogerontology, which is the underlying mechanisms of aging, anti-aging drugs, cancer, and targeted cancer therapies that guard the healthy cells against being damaged.

Dr. Blagosklonny is the editor-in-chief of Oncotarget and Cell Cycle and the associate editor of Cancer Biology and Therapy. He is also in the Cell Death and Differentiation editorial board.His hypothesis regarding TOR Signaling potential role in cancer and aging is that the common cancer fighting drug called Rapamycin can be used to extend a person’s life. He is also one of the most passionate advocates for this drug in longevity research. In one of his research endeavors, he tested out a drug called Everolimus, which is a drug that is very comparable to Rapamycin. He found that this drug was actually shown to improve immunity in older humans. This was groundbreaking research and a huge win for Mikhail.

He has so many different types of research that he does. Some of those are: tumor suppressors, cell cycle, and mitosis. Along with all of this, he is also the author of Aging Hyperfunction Theory. Additionally, he has written about cell cyclotherapy and chemotheraputic engineering.He really believes that you can control aging and cancer and that cancer can be cured. He has 300 research articles, book chapters, and reviews that are published under his name so you can see that he is very serious and passionate about his work. Because of this, he is one of the biggest oncology researchers in the entire world.As you can see, Mikhail Blagosklonny really believes in the work and research he does and stands behind all of his statements and publications. If we have a world where aging is abolished, there are endless possibilities for this life. He is working hard and is dedicated to figuring out how to stop aging from happening.

Impact of Clay Siegall in Cancer Treatment

Clay Siegall is the co-founder, President, the Chief Executive Officer, and the Chairman of the Board of Directors of Seattle Genetics. Clay Siegall founded the company in 1998 after working in different medical institutions such as the National Cancer Institute, National Institutes, Bristol-Myers Squibb Pharmaceutical Research Institute, and BioPharmaceuticals. Dr. Siegall has a Ph.D. in Genetics and a B.S in Zoology from George Washington University and the University of Maryland respectively.

Seattle Genetics has seen massive developments under the leadership of Dr. Clay Siegall. Through his leadership, the firm was able to secure an FDA approval of its ADC product, ADCETRIS in 2011. He has also guided the company in developing antibody-drug conjugates (ADCs). He has also helped make ADCETRIS a global drug through collaboration with Takeda Pharmaceutical Company. Dr. Siegall has made Seattle Genetics grow into a diverse production of ADCs for the treatment of cancer.

Dr. Siegall has aided in the fight against cancer by the production of cancer vaccines and sitting in multiple cancer boards. He has helped Seattle Genetics enter multiple strategic licenses that have seeded more than $350 million.

Dr. Siegall is an author of more than 70 publications, articles and holds 15 patents. Some of his articles are discussed below.

Why are people not using a vaccine that can significantly change the lives of many people living with cancer? Human papillomavirus (HPV) vaccine is a vaccine which was discovered over a decade ago and can prevent more than 90% of all cervical cancers, other cancers, and sexually transmitted infections. However, the vaccine has not gained popularity as it is supposed to have. To get the virus to most people around the world, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices have reduced the HPV dose from three to two for kids between 9 and 14 years.

Researchers have discovered a new machine called BrainGate2. The device allows paralyzed people to decode their thoughts and control their muscles and organs such as arms. The device operates by determining the movement which an individual wants to perform; then it electrically stimulates the muscles in the arm to perform the movement.